Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ophthalmic drug approvals, compounding economics, and FDA milestones make Harrow Health’s disclosures dense reading. If you have ever searched for “Harrow Health SEC filings explained simply” or wished for a “Harrow Health annual report 10-K simplified,” you know how quickly technical jargon slows real analysis. Stock Titan’s AI-driven platform opens every Harrow filing with context, highlighting how its Dextenza distribution agreements, in-office sedation products, and research expenses shape long-term value.
Need the numbers fast? Our tool streams each “Harrow Health quarterly earnings report 10-Q filing” the moment it hits EDGAR, then produces a concise “Harrow Health earnings report filing analysis” that isolates revenue per ophthalmic segment, compounding margins, and cash runway. It also decodes Form 8-K notices—think “Harrow Health 8-K material events explained”—so you instantly see how licensing deals or FDA complete response letters may move the stock. In short, you’re “understanding Harrow Health SEC documents with AI,” not digging through footnotes.
Monitoring management behavior is just as effortless. Receive alerts for “Harrow Health insider trading Form 4 transactions,” review “Harrow Health Form 4 insider transactions real-time,” and compare option grants under the “Harrow Health executive stock transactions Form 4” label. Preparing for the annual meeting? Our AI highlights board pay metrics inside every “Harrow Health proxy statement executive compensation” section. From 10-K to 8-K, Stock Titan delivers complete coverage, real-time updates, and expert clarity—so you spend time acting on insights, not hunting for them.
Harrow, Inc. (HROW) filed a Form 4 disclosing a stock option grant to Chief Accounting Officer Randall E. Pollard. On 09/01/2025 Mr. Pollard was granted an option to purchase 30,000 shares of common stock at an exercise price of $39 per share. The option expires on 09/01/2035 and is exercisable according to a vesting schedule: 25% at the one-year anniversary and the remainder vesting in 12 equal quarterly installments, becoming fully vested and exercisable on 09/01/2029. The filing was signed by an attorney-in-fact on 09/09/2025.
Randall E. Pollard, the Chief Accounting Officer of Harrow, Inc. (HROW), filed an initial Form 3 reporting that he does not beneficially own any securities of the company. The event requiring the statement is dated
Harrow, Inc. reported stronger product sales and improved operating performance for the quarter and six months ended June 30, 2025. Product sales for the three months were $63,657,000 compared with $48,871,000 a year earlier, and total revenues for the three months were $63,742,000 versus $48,939,000. Gross profit for the quarter was $47,512,000, driving a GAAP net income of $4,995,000 for the three months ended June 30, 2025, compared with a net loss of $6,473,000 in the prior-year quarter.
For the six months ended June 30, 2025, total revenues were $111,573,000 versus $83,526,000 a year earlier and the company reported a net loss of $12,785,000, an improvement from a $20,038,000 loss in the prior-year period. Cash and cash equivalents increased to $52,963,000 and operating activities provided $18,865,000 of cash during the six months. Material near-term financing items exist: the Oaktree Loan ($107,500,000 principal) and the 2026 Notes ($75,000,000) mature in January and April 2026, and management is pursuing refinancing or asset sales but notes there is no assurance of success, stating these maturities could raise substantial doubt about the company’s ability to continue as a going concern.
FAQ
What is the current stock price of Harrow Health (HROW)?
What is the market cap of Harrow Health (HROW)?
